Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.62 |
| ▸ | RARB | P10826 | 9/20 | 0.62 |
| ▸ | RARG | P13631 | 9/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874221 | 0.92 | RARA (0.74) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7874223 | 0.92 | RARA (0.74) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8026108 | 0.88 | RARA (0.80) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807072 | 0.86 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807064 | 0.86 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7874215 | 0.79 | RARB (0.57) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6754156 | 0.79 | RARA (0.78) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6754150 | 0.79 | RARA (0.78) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807078 | 0.79 | RARA (0.55) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7800427 | 0.78 | RARB (0.60) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003780-A1 | Retinoid antagonists and uses thereof | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.